Elevated plasma macrophage migration inhibitor factor is associated with hypertension and hypertensive left

Ling Zhu1,2, Shasha Chen3, Na Liu4

  • 1Department of Cardiology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, 710000, China.

Insights

Elevated macrophage migration inhibitor factor (MIF) is linked to hypertension and hypertensive left ventricular hypertrophy. Higher MIF levels significantly increase the risk of developing these cardiovascular conditions.

Area of Science:

  • Cardiovascular Research
  • Biomarkers
  • Hypertension Research

Background:

  • Macrophage migration inhibitor factor (MIF) is implicated in endothelial dysfunction and ventricular remodeling.
  • Understanding MIF's role in hypertension and associated cardiac changes is crucial for cardiovascular health.

Purpose of the Study:

  • To investigate the association between plasma MIF levels and the presence of hypertension.
  • To explore the relationship between plasma MIF levels and hypertensive left ventricular hypertrophy (LVH).

Main Methods:

  • A cohort of 308 participants, including 187 hypertensive patients and 121 healthy controls, was studied.
  • Univariate and multivariate logistic regression models were used to assess associations.
  • Correlation and receiver operating characteristic (ROC) analyses were performed.

Main Results:

  • Elevated MIF levels were significantly associated with an increased risk of hypertension.
  • Plasma MIF levels strongly correlated with hypertensive left ventricular mass index (r=0.580, P<0.001).
  • Higher MIF levels were strongly associated with hypertensive LVH, with significant odds ratios (e.g., OR 24.95 for the highest tertile).
  • ROC analysis showed MIF has good predictive accuracy for hypertensive LVH (AUC=0.84).

Conclusions:

  • Elevated plasma macrophage migration inhibitor factor is a significant risk factor for hypertension.
  • Increased MIF levels are closely associated with hypertensive left ventricular hypertrophy, suggesting its role as a potential biomarker.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
95
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
84
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
135